Shih Li Lin, MD
Hematology & Oncology · Seattle, WANPI 1912100371
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Exelixis Inc. at 38.8% of the total. Reporting peaked in 2021 at $3,870 and has fallen 51.2% since, to $1,889 in 2025.
Across 28 payments — averaging $463.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$5K
- Array Biopharma Inc$2K
- AstraZeneca$2K
- Seagen Inc.$1K
- Genentech USA, Inc.$1K
- Bayer$900
- plus $624 from 7 others
Across 627 payments — averaging $6843.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.6M
- Exelixis Inc.$1M
- Incyte Corporation$579K
- Genentech, Inc.$469K
- GSK$306K
- Taiho Oncology, Inc.$146K
- plus $167K from 7 others
What the payments were for
- Consulting fees$3,80029%
- Speaking & faculty fees$6,32049%
- Travel & lodging$1,73413%
- Food & beverage$1,1229%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 11 | $5,035 |
| Array Biopharma Inc | 1 | $2,400 |
| AstraZeneca | 1 | $1,675 |
| Seagen Inc. | 1 | $1,225 |
| Genentech USA, Inc. | 6 | $1,117 |
| Bayer | 1 | $900 |
| Astellas Pharma US Inc | 1 | $149 |
| Verastem, Inc. | 1 | $127 |
| Shockwave Medical, Inc | 1 | $124 |
| Genentech, Inc. | 1 | $87 |
| Sirtex Medical Inc | 1 | $77 |
| Merck | 1 | $46 |
| BD | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,976 in reported general payments places this provider in the 80th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 21 | $480,311 |
| Imatinib Mesylate | 40 | $115,592 |
| CreonLipase/Protease/Amylase | 42 | $109,992 |
| EliquisApixaban | 74 | $63,319 |
| XareltoRivaroxaban | 14 | $16,265 |
| Enoxaparin Sodium | 33 | $9,273 |
| Dexamethasone | 43 | $815 |
| Potassium Chloride | 28 | $668 |
| Anastrozole | 23 | $649 |
| Omeprazole | 30 | $430 |
| Prochlorperazine Maleate | 48 | $414 |
| Duloxetine Hcl | 15 | $369 |
| Gabapentin | 30 | $317 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 15 | $307 |
| Ondansetron Hcl | 33 | $265 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Seattle
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Celestia HiganoSeattle$164K
- Ryan CassadaySeattle$151K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.